QurAlis Overview
- Year Founded
-
2016
- Status
-
Private
- Employees
-
87
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$20M
- Investors
-
19
QurAlis General Information
Description
Developer of precision therapeutics and tools designed for amyotrophic lateral sclerosis and other neurodegenerative diseases with genetically validated targets. The company's proprietary platforms and biomarkers offer the design and development of drugs that act directly on disease-causing genetic alterations, advancing a robust precision medicine pipeline with therapeutic candidates that modify severe disease pathology in defined patient populations based on both disease-causing genetic mutation and clinical biomarkers, enabling medical professionals to halt disease progression and significantly improve outcomes.
Contact Information
Website
www.quralis.comCorporate Office
- 35 Cambridgepark Drive
- Suite 300
- Cambridge, MA 02140
- United States
Corporate Office
- 35 Cambridgepark Drive
- Suite 300
- Cambridge, MA 02140
- United States
QurAlis Timeline
QurAlis Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Later Stage VC | 04-Sep-2025 | $20M | Completed | Clinical Trials - Phase 1 | ||
| 8. Secondary Transaction - Private | Completed | Clinical Trials - Phase 1 | ||||
| 7. Later Stage VC (Series B) | 09-Mar-2023 | Completed | Clinical Trials - Phase 1 | |||
| 6. Accelerator/Incubator | 01-Jan-2022 | Completed | Clinical Trials - Phase 1 | |||
| 5. Early Stage VC (Series A1) | 13-May-2020 | Completed | Clinical Trials - Phase 1 | |||
| 4. Early Stage VC (Series A) | Completed | Clinical Trials - Phase 1 | ||||
| 3. Early Stage VC (Series A) | 19-Nov-2018 | Completed | Clinical Trials - Phase 1 | |||
| 2. Accelerator/Incubator | Completed | Clinical Trials - Phase 1 | ||||
| 1. Accelerator/Incubator | Completed | Clinical Trials - Phase 1 |
QurAlis Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B-2 | ||||||||
| Series B-1 | ||||||||
| Series A1 | ||||||||
| Series A3 | 980,744 | $0.000100 | $3.06 | $3.06 | 1x | $3.06 | 1.69% | |
| Series A2 | 4,145,771 | $0.000100 | $2.22 | $2.22 | 1x | $2.22 | 7.12% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
QurAlis Comparisons
Industry
Financing
Details
QurAlis Competitors (9)
One of QurAlis’s 9 competitors is Verge Labs, a Venture Capital-Backed company based in San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Verge Labs | Venture Capital-Backed | San Francisco, CA | ||||
| LeonaBio | Formerly VC-backed | Bothell, WA | ||||
| Amylyx Pharmaceuticals | Formerly VC-backed | Cambridge, MA | ||||
| Biohaven | Formerly VC-backed | New Haven, CT | ||||
| Xenon Pharmaceuticals | Formerly VC-backed | Burnaby, Canada |
QurAlis Patents
QurAlis Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026080735-A1 | Functionalized tetrahydrofuran intermediate and synthesis thereof | Pending | 09-Oct-2024 | ||
| WO-2026080323-A1 | Treatment of neurological diseases using modulators of unc13a gene transcripts | Pending | 09-Oct-2024 | ||
| EP-4720083-A1 | Functionalized tetrahydrofuran intermediate and synthesis thereof | Pending | 02-Jun-2023 | ||
| WO-2024249886-A1 | Functionalized tetrahydrofuran intermediate and synthesis thereof | Inactive | 02-Jun-2023 | ||
| AU-2024283557-A1 | Modified unc13a oligonucleotides | Pending | 02-Jun-2023 | A61K31/712 |
QurAlis Signals
QurAlis Investors (19)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| ALS Investment Fund | Venture Capital | Minority | ||
| EQT Life Sciences | Venture Capital | Minority | ||
| Pimlico Pond Investments | Family Office | Minority | ||
| Sanofi Ventures | Corporate Venture Capital | Minority | ||
| Termeer Institute | Accelerator/Incubator |
QurAlis FAQs
-
When was QurAlis founded?
QurAlis was founded in 2016.
-
Where is QurAlis headquartered?
QurAlis is headquartered in Cambridge, MA.
-
What is the size of QurAlis?
QurAlis has 87 total employees.
-
What industry is QurAlis in?
QurAlis’s primary industry is Therapeutic Devices.
-
Is QurAlis a private or public company?
QurAlis is a Private company.
-
What is QurAlis’s current revenue?
The current revenue for QurAlis is .
-
How much funding has QurAlis raised over time?
QurAlis has raised $158M.
-
Who are QurAlis’s investors?
ALS Investment Fund, EQT Life Sciences, Pimlico Pond Investments, Sanofi Ventures, and Termeer Institute are 5 of 19 investors who have invested in QurAlis.
-
Who are QurAlis’s competitors?
Verge Labs, LeonaBio, Amylyx Pharmaceuticals, Biohaven, and Xenon Pharmaceuticals are some of the 9 competitors of QurAlis.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process